The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis

The Lyon-Marseille-Curie-Est (LMCE) of France cooperative group has previously reported successive series of unselected stage four children older than 1 year at diagnosis with metastatic neuroblastoma (LMCE 1 and 3). The goal of LMCE 5 study was to increase progression free survival rate as compared...

Descripción completa

Detalles Bibliográficos
Autores principales: Frappaz, D, Perol, D, Michon, J, Berger, C, Coze, C, Bernard, J L, Zucker, J M, Philip, T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2002
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408899/
https://www.ncbi.nlm.nih.gov/pubmed/12439705
http://dx.doi.org/10.1038/sj.bjc.6600627
_version_ 1782155717339250688
author Frappaz, D
Perol, D
Michon, J
Berger, C
Coze, C
Bernard, J L
Zucker, J M
Philip, T
author_facet Frappaz, D
Perol, D
Michon, J
Berger, C
Coze, C
Bernard, J L
Zucker, J M
Philip, T
author_sort Frappaz, D
collection PubMed
description The Lyon-Marseille-Curie-Est (LMCE) of France cooperative group has previously reported successive series of unselected stage four children older than 1 year at diagnosis with metastatic neuroblastoma (LMCE 1 and 3). The goal of LMCE 5 study was to increase progression free survival rate as compared to LMCE 1 and 3. Based on improvements reported with post induction chemotherapy, the LMCE 5 used post induction for all children, but omitted total body irradiation and immunomagnetic purging in megatherapy regimen for all children. Twenty-five sequentially diagnosed children received an induction regimen which compared with previous induction included an increased dose of etoposide and cyclophosphamide, delivered similar dose of cisplatinum, and deleted doxorubicin and vincristin. After surgery treatment was stratified based on response and eligible children received etoposide carboplatin (LMCE 5A : n=10)±doxorubicin (LMCE 5B–C n=13) followed by megatherapy (melphalan without total body irradiation and unpurged peripheral blood stem cell rescue). The increase in drug doses during induction did not improve remission rate. The progression free survival at 6 years is 8%. It is significantly worse than LMCE 3, and equivalent to LMCE 1 study though toxic death rate has decreased with increasing experience. Failure to improve the response rate during induction and reducing the megatherapy regimen may be the main factors in this disappointing result. Modified strategies for induction, non toxic alternative to total body irradiation, and post megatherapy regimen should be developed. British Journal of Cancer (2002) 87, 1197–1203. doi:10.1038/sj.bjc.6600627 www.bjcancer.com © 2002 Cancer Research UK
format Text
id pubmed-2408899
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24088992009-09-10 The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis Frappaz, D Perol, D Michon, J Berger, C Coze, C Bernard, J L Zucker, J M Philip, T Br J Cancer Clinical The Lyon-Marseille-Curie-Est (LMCE) of France cooperative group has previously reported successive series of unselected stage four children older than 1 year at diagnosis with metastatic neuroblastoma (LMCE 1 and 3). The goal of LMCE 5 study was to increase progression free survival rate as compared to LMCE 1 and 3. Based on improvements reported with post induction chemotherapy, the LMCE 5 used post induction for all children, but omitted total body irradiation and immunomagnetic purging in megatherapy regimen for all children. Twenty-five sequentially diagnosed children received an induction regimen which compared with previous induction included an increased dose of etoposide and cyclophosphamide, delivered similar dose of cisplatinum, and deleted doxorubicin and vincristin. After surgery treatment was stratified based on response and eligible children received etoposide carboplatin (LMCE 5A : n=10)±doxorubicin (LMCE 5B–C n=13) followed by megatherapy (melphalan without total body irradiation and unpurged peripheral blood stem cell rescue). The increase in drug doses during induction did not improve remission rate. The progression free survival at 6 years is 8%. It is significantly worse than LMCE 3, and equivalent to LMCE 1 study though toxic death rate has decreased with increasing experience. Failure to improve the response rate during induction and reducing the megatherapy regimen may be the main factors in this disappointing result. Modified strategies for induction, non toxic alternative to total body irradiation, and post megatherapy regimen should be developed. British Journal of Cancer (2002) 87, 1197–1203. doi:10.1038/sj.bjc.6600627 www.bjcancer.com © 2002 Cancer Research UK Nature Publishing Group 2002-11-18 2002-11-12 /pmc/articles/PMC2408899/ /pubmed/12439705 http://dx.doi.org/10.1038/sj.bjc.6600627 Text en Copyright © 2002 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
Frappaz, D
Perol, D
Michon, J
Berger, C
Coze, C
Bernard, J L
Zucker, J M
Philip, T
The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis
title The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis
title_full The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis
title_fullStr The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis
title_full_unstemmed The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis
title_short The LMCE5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis
title_sort lmce5 unselected cohort of 25 children consecutively diagnosed with untreated stage 4 neuroblastoma over 1 year at diagnosis
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408899/
https://www.ncbi.nlm.nih.gov/pubmed/12439705
http://dx.doi.org/10.1038/sj.bjc.6600627
work_keys_str_mv AT frappazd thelmce5unselectedcohortof25childrenconsecutivelydiagnosedwithuntreatedstage4neuroblastomaover1yearatdiagnosis
AT perold thelmce5unselectedcohortof25childrenconsecutivelydiagnosedwithuntreatedstage4neuroblastomaover1yearatdiagnosis
AT michonj thelmce5unselectedcohortof25childrenconsecutivelydiagnosedwithuntreatedstage4neuroblastomaover1yearatdiagnosis
AT bergerc thelmce5unselectedcohortof25childrenconsecutivelydiagnosedwithuntreatedstage4neuroblastomaover1yearatdiagnosis
AT cozec thelmce5unselectedcohortof25childrenconsecutivelydiagnosedwithuntreatedstage4neuroblastomaover1yearatdiagnosis
AT bernardjl thelmce5unselectedcohortof25childrenconsecutivelydiagnosedwithuntreatedstage4neuroblastomaover1yearatdiagnosis
AT zuckerjm thelmce5unselectedcohortof25childrenconsecutivelydiagnosedwithuntreatedstage4neuroblastomaover1yearatdiagnosis
AT philipt thelmce5unselectedcohortof25childrenconsecutivelydiagnosedwithuntreatedstage4neuroblastomaover1yearatdiagnosis
AT frappazd lmce5unselectedcohortof25childrenconsecutivelydiagnosedwithuntreatedstage4neuroblastomaover1yearatdiagnosis
AT perold lmce5unselectedcohortof25childrenconsecutivelydiagnosedwithuntreatedstage4neuroblastomaover1yearatdiagnosis
AT michonj lmce5unselectedcohortof25childrenconsecutivelydiagnosedwithuntreatedstage4neuroblastomaover1yearatdiagnosis
AT bergerc lmce5unselectedcohortof25childrenconsecutivelydiagnosedwithuntreatedstage4neuroblastomaover1yearatdiagnosis
AT cozec lmce5unselectedcohortof25childrenconsecutivelydiagnosedwithuntreatedstage4neuroblastomaover1yearatdiagnosis
AT bernardjl lmce5unselectedcohortof25childrenconsecutivelydiagnosedwithuntreatedstage4neuroblastomaover1yearatdiagnosis
AT zuckerjm lmce5unselectedcohortof25childrenconsecutivelydiagnosedwithuntreatedstage4neuroblastomaover1yearatdiagnosis
AT philipt lmce5unselectedcohortof25childrenconsecutivelydiagnosedwithuntreatedstage4neuroblastomaover1yearatdiagnosis

Ejemplares similares